WO2007016954A1 - Composition for reducing drug or alcohol induced breast cancer risk - Google Patents
Composition for reducing drug or alcohol induced breast cancer risk Download PDFInfo
- Publication number
- WO2007016954A1 WO2007016954A1 PCT/EP2005/009152 EP2005009152W WO2007016954A1 WO 2007016954 A1 WO2007016954 A1 WO 2007016954A1 EP 2005009152 W EP2005009152 W EP 2005009152W WO 2007016954 A1 WO2007016954 A1 WO 2007016954A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- food composition
- dietary supplementation
- alcohol
- dose
- supplementation according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 15
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 46
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 40
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 20
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 15
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 14
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000018417 cysteine Nutrition 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 12
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 10
- 239000008121 dextrose Substances 0.000 claims abstract description 10
- 235000019192 riboflavin Nutrition 0.000 claims abstract description 10
- 229960002477 riboflavin Drugs 0.000 claims abstract description 10
- 239000002151 riboflavin Substances 0.000 claims abstract description 10
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 9
- 239000001530 fumaric acid Substances 0.000 claims abstract description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 8
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 8
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 8
- 239000011718 vitamin C Substances 0.000 claims abstract description 8
- 238000006731 degradation reaction Methods 0.000 claims abstract description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 5
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims abstract description 5
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 5
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 70
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 27
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims description 18
- 239000005515 coenzyme Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 7
- 230000003647 oxidation Effects 0.000 claims description 7
- 238000007254 oxidation reaction Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 230000004149 ethanol metabolism Effects 0.000 claims description 6
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 238000009825 accumulation Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000000354 decomposition reaction Methods 0.000 claims description 4
- 239000001384 succinic acid Substances 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 229930003537 Vitamin B3 Natural products 0.000 claims description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 3
- 235000019160 vitamin B3 Nutrition 0.000 claims description 3
- 239000011708 vitamin B3 Substances 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 2
- 101100476962 Drosophila melanogaster Sirup gene Proteins 0.000 claims 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 230000009467 reduction Effects 0.000 abstract description 4
- 235000011087 fumaric acid Nutrition 0.000 abstract description 3
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 230000009894 physiological stress Effects 0.000 abstract description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 abstract 1
- 229960001031 glucose Drugs 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 29
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 11
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 9
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 6
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 6
- BOPGDPNILDQYTO-NNYOXOHSSA-L NADH(2-) Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-L 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000035622 drinking Effects 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 3
- 235000013334 alcoholic beverage Nutrition 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 3
- 239000005516 coenzyme A Substances 0.000 description 3
- 229940093530 coenzyme a Drugs 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 206010019133 Hangover Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 238000010405 reoxidation reaction Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention is directed to a composition, in particular a food composition, or dietary supplementation which is active in respect to the support and/or the moderation of an alcohol degradation process within the human body. The present invention particularly addresses the problem of rapid alcohol degradation i.e. alcohol metabolism as may occur in most people of Non-Caucasian type genetic structure. In this regard, an object of the present invention is to achieve solutions which provide a reduction in the physiological stress in connection with the consumption of alcohol in particular for people with a predisposition towards rapid alcohol degradation. According to the present invention this object is attained by a food composition or dietary supplementation including the following substances: niacin, dextrose, Vitamin C, L-glutamine cysteine, riboflavin, succinic acid, fumaric acid, and coenzyme Q 10, all substances in physiologically relevant doses in particular as disclosed. The composition reduces drug or alcohol induced breast cancer.
Description
COMPOSITION FOR REDUCING DRUG OR ALCOHOL INDUCED
BREAST CANCER RISC
The present invention is directed to a composition, in particular a food composition, or dietary supplementation, which is active in respect to a reduction of drug or alcohol induced breast cancer rise. In this respect the invention is directed to a composition affecting the moderation of a drug, or alcohol degradation process within the human body.
In this regard, an object of the present invention is to achieve solutions which provide a reduction in the toxic effects or physiological stress in connection with the consumption of drugs, and/or alcohol, in particular for people with a predisposition towards rapid alcohol degradation and subsequent accumulation of acetaldehyde due to a genetic polymorphism of human acetaldehyde-dehydrogenase enzym.
According to the present invention this object is attained by a food composition, or dietary supplementation including the following substances:
dextrose, Vitamin C, L-glutamine cysteine, riboflavin, succinic acid, fumaric acid, coenzyme QlO, and niacin.
all substances in physiologically relevant doses.
With this particular food composition, or dietary supplementation it will become possible to reduce the activity, or to suppress the production of a particular alcohol dehydrogenase enzyme (ADH3), to slow down the production of acetaldehyde and
the ethanol metabolism process and reduce the alcohol induced peak load on the human organism. Further the enzymatic activity of aldehyde dehydrogenase ALDH2 will be enhanced, so that the metabolisation of acetaldehyde will be supported.
These particular effects help to reduce the peak load of critical substances on the human body, and further reduce a flushing syndrome, reduce the likelihood of headaches and also help to avoid or ease a hangover the day after.
The present invention particularly solves the problem of a long impact of an accumulation of acetaldehyde after rapid alcohol degradation i.e. alcohol metabolism as may occur in most people of Non-Caucasian type genetic structure.
The particular food composition or dietary supplementation is considered to be appropriate to reduce a peak of excess acetaldehyde entering the blood stream and is intended to lower the risk of damage to vital organs and functions of the human body, and in this connection particularly lowers the risk of breast cancer.
It is considered as evident that drinking alcoholic beverages is associated with increases risk for certain kinds of cancer including breast cancer . The association of alcohol consumption with increased risk for breast cancer is considered as beeing evident at least implicitly from epidemiological studies indicating that alcohol itself and/or its metabolite(s) has carcinogenic potency.
Ethanol taken into the body is eliminated by its oxidation. Ethanol is first metabolised to acetaldehyde by alcohol dehydrogenase (ADH), and then acetaldehyde is further metabolised to acetic acid by aldehyde dehydrogenase (ALDH). Increased estrogen levels in women drinkers appear to be an important mechanism for development of breast cancer.
One possible mechanism for the increase of estrogen is that overproduced acetic acid after drinking is converted to steroids. However, the first metabolite of orally ingested alcohol, acetaldehyde, is suspected to play a pivotal role in the development of alcohol related cancers of other tissues, because of its established
DNA damaging effects (single-strand and double-strand breaks) and carcinogenicity in laboratory animals. The, possible role of acetaldehyde for the alcohol-induced breast cancer appears to be evident. There are polymorphic isoforms of ALDH and class 2 ALDH (ALDH2), which has the lowest affinity constant (Km), is the most important enzyme for acetaldehyde oxidation. A mutant allele ALDH2*2, has a single point mutation (G-»A) in exon 12 of the active ALDH2*1 gene.
This mutation results in a substitution of glutamic acid (GIu) at amino acid position 487 by lysine (Lys), acting in a dominant negative fashion. This mutation is confined to Orientals. Acetaldehyde oxidation is strikingly impaired in individuals with ALDH2*2 allele. It is expected that ALDH2 deficiency is associated with an increase of the risk of breast cancer.
Acetaldehyde has a lipophilic nature and accumulates in adipose tissues. Mammary gland is enriched in fat and other lipophilic tissues. It is concluded that drinking alcoholic beverages is associated with increases risk for breast cancer. The possible role of acetaldehyde for the alcohol-induced breast cancer is thus assumed. Therefore, it is reasonable to expect that acetaldehyde plays, if any small, a role in the carcinogenesis of mammary glands.
The proposed composition, in particular supplement mix accelerates the metabolism of alcohol and acetaldehyde. This mixture decreases the concentration of blood acetaldehyde. Moreover, the disclosed supplement is expected to efficiently eliminate acetic acid through activation of TCA cycle and electron transport system, and consequently to prevent the synthesis of steroids including estrogen. Therefore, the supplement according to the invention has a possibility to reduce the risk of breast cancer for alcohol drinkers, especially those who have ALDH2*2 allele.
The niacin-fraction (Vitamin B3) included in the composition functions as nicotinamide adenine dinucleotide (NAD), which is effective towards a coenzyme to alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). This vitamin is provided to accelerate ethanol metabolism.
According to a particularly preferred embodiment, the composition also includes Pantotheic acid. Pantotheic acid functions as coenzyme A (CoA), which is considered necessary to metabolize acetic acid. Acetic acid is activated in conjugation with CoA to form acetyl-CoA, which is metabolized in TCA cycle. In enzymatical point of view, elimination of a product (acetic acid) is effective towards an acceleration of the metabolism of a substrate (acetaldehyde).
Preferably this food composition or supplements should be taken about 5 minutes prior to consumption of alcohol and in case of high alcohol consumption again whilst consuming alcohol. The mass of the food composition taken by the consumer should be in the range of about 70 to 120% of the mass of the alcohol included in the consumed drinks. A standard dose might include about 10. Og dextrose, 1.Og Vitamin C, 1.5g L-glutamine, 500mg cysteine, 40mg riboflavin, 100 mg succinic acid, 100 mg fumaric acid, 60mg coenzyme QlO, and about 10 mg Niacin (Vitamin B3). Preferably the relation of the components of the composition is oriented towards the above given relation. The overall dosage may be adapted to the body mass weight of the consumer.
The particular food composition, or dietary supplementation is intended to prevent too much acetaldehyde passing into the mitochondrial matrix and to suppress self- blockade of the enzymatic activity of ALDH and thus facilitate its the decomposition of acetaldehyde.
The physiological risks in connection with alcohol consumption may therefore be significantly reduced by the use of the food composition according to the present invention, as this food composition or dietary supplementation facilitates in a synergetic manner an early decrease of the level of acetaldehyde after drinking and simultaneously provides a protective effect in respect of the suppression of the generation of free radicals.
Said food composition or dietary supplementation is preferably in such a form, preferably as ingredients of a kind of aperitif, that it allows the food composition to
be consumed within a restaurant or a bar prior to consuming alcoholic drinks. Preferably a dosage for a person with a body weight of about 80 kg includes a dextrose fraction of approx. 75%, wherein the said dosage may have an overall weight of about 10 to 15, preferably 13.3g. Such a dosage is to provide a considerable moderation in degrading about 18ml alcohol.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same, includes a dextrose fraction of about 75.2 mass%, i.e. a quantity of dextrose in the range from 7.2 to 12.8g, preferably 10.0 g within a dose of 13,3 g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a Vitamin C fraction of about 7.5 mass% i.e a quantity of Vitamin C in the range from 0.78 to 1.18 g, preferably 1.Og, within a dose of 13.3g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a L-glutamine fraction of about 11.27 mass%, i.e. a quantity of said L-glutamine fraction in the range from 1.23 to 1.7 g, preferably 1.5g, within a dose of 13.3g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a cysteine fraction of about 3.76 mass%, i.e. a quantity of said cysteine fraction in the range from 460 to 540 mg, preferably 500mg, within a dose of 13.3g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a riboflavin fraction of about 0.30 mass% i.e. a quantity of said riboflavin in the range from 32 to 48 mg, preferably 40mg, within a dose of 13.3 g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a succinic acid (Bernsteinsaure) fraction
of about 0.752 mass%, i.e. a quantity of said succinic acid in the range from 90 to 110 mg, preferably lOOmg, within a dose of 133g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a fumaric acid (Fumarsaure) fraction of about 0.752 mass%, i.e. a quantity of said fumaric acid in the range from 90 to 110 mg, preferably lOOmg, within a dose of 13.3g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a coenzyme fraction of about 0,451 mass%, i.e. a quantity of said coenzyme fraction in the range from 50 to 70 mg, preferably 60mg, within a dose of 13.3g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same is in the form of tablets. Preferably, each tablet is so shaped and dimensioned that it allows said tablet to be easily swallowed.
Preferably, said tablets are in such a form that one dosage includes a plurality of those tablets.
The tablets may be accommodated within a dosage receptacle which includes a number of those tablets. It is possible for the food composition to be in the form of small tablets or balls, and to keep same in a small tube, while the volume of the food composition taken by the consumer can be determined with respect to the volume of alcohol which is expected to be consumed.
The food composition or dietary supplementation may also be in a form similar to sugar-cubes, or might be in the form of cryopowder.
The food composition or dietary supplementation may be separated into separate subunits. It is possible to provide one unit, for example a capsule including the Vitamin C fraction, cysteine, riboflavin, succinic acid, fumaric acid and coenzyme
QlO, whilst most of the dextrose fraction is kept in separate units, capsules, tablets or the like.
It is possible to add further substances such as fruit juice extracts, curcuma, tannin, a powder of Panax notoginseng, and Vinca rosea in suitable amounts. Oolong tea, aloe vera and spiral water algae might also be added.
The food-composition or dietary supplementation may also be in the form of a liquid, in particular a sirup-type liquid. It is possible to provide the food composition in the appearance of a soft drink in a small bottle.
The particular food composition or dietary supplementation is considered to provide the following achievements:
1. Reduction of ethanol metabolism by slowing down the process of ethanol oxidation into acetaldehyde, to prevent accumulation of acetaldehyde in the first place.
2. Stimulation of the activity of ALDH and avoiding any blockade of its enzymatic activity.
3. Speeding up the reaction from acetaldehyde to acetic acid and the further decomposition in the citrate cycle.
4. Improving the levels of those anti-oxidants of the alcohol consumer, which specially protect against toxic effects of acetaldehyde.
The first achievement
is believed to be reached by the intake of a large dose of dextrose sugar (glucose). Glucose is rapidly oxidised in the cytosol of liver cells using the same cytosol NAD+ pool used by ethanol to be converted into acetaldehyde. Because the amount of cytosolic NAD+ is limited and can only constantly be reproduced from NADH+H much less acetaldehyde accumulates.
The second achievement is also believed to be achieved by the intake of a large dose of glucose. Glucose augments the enzymatic activity of ADH as well as of ALDH. When a large glucose load occurs in the cytosol of liver cells then there is no possibility that the acetaldehyde reaches levels which could lead to inactivation of ALDH or to mitochondrial destruction.
The third achievement
is believed to be performed by
a) Accelerating the reoxidation from NADH+H+ to NAD+ by speeding up the transport of electrons through the inner mitochondrial membrane
b) Accelerating the Krebs cycle
It is believed to be achieved by the inclusion of coenzyme Qi0 and riboflavin. Riboflavin will quickly be transformed to FMN, which together with coenzyme Qi0 is the determining substance for the speed of the reoxidation of NADH+H+ to NAD+ in the mitochondrial matrix. Acetaldehyde needs NAD+ when it is metabolised to acetic acid. Within this reaction NAD+ is transformed into NADH+H+. Because the availability of NAD+ is limited in the mitochondrial matrix NADH+H+ has to be re-transformed into NAD+ to serve again for acetaldehyde decomposition. This reaction is only possible because FMN and coenzyme Qi0 absorb the electrons of NADH+H+ and shuttle them through the mitochondrial membrane. The more FMN and coenzyme Qi0 are available, the more this process is speeded up and, because more NAD+ is available, the metabolism of acetaldehyde is accelerated.
The inclusion of coenzyme Qi0 also makes also sense because its level decreases in the human body with progressing age.
The activation of the Krebs (citrate) cycle is believed to be achieved by the inclusion of succinic acid and fumaric acid. Both substances activate the second half of the citrate cycle and thereby activate the aerobic oxidation process in mitochondria. L-glutamine helps to speed up the mitochondria-cytosolic malate- asparate shuttle, which plays a key role in the course of intoxication by acetaldehyde. It also speeds up the succinate oxidation process by preventing oxalic and acetic inhibition of succinate dehydrogenase.
The fourth achievement,
the elevation of anti-oxidant levels, is believed to be achieved by the inclusion of cysteine, ascorbic acid and also of L-glutamine. Cysteine should provide a strong anti-oxidant effect as well as ascorbic acid. The human body transforms cysteine to gluthatione which specially protects against the toxic effects of acetaldehyde. To reach an optimal level of gluthatione and to avoid cysteine being transformed to cystine, it is important to combine cysteine with glutamine and give twice as much ascorbic acid as cysteine.
By taking the mentioned substances, it is expected that the level of acetaldehyde after drinking alcohol will be remarkably reduced and flushing symptoms at least diminished. The other known side-effects of acetaldehyde such as headaches and hangovers should also disappear.
Claims
1. Food composition, or dietary supplementation for reducing drug, or alcohol induced breast cancer rise by moderating a drug or alcohol degradation process in respect to ethanol metabolism within the human body, including the following substances in physiologically relevant amount:
niacin (Vitamin B3), dextrose,
Vitamin C,
L-glutamine, cysteine, riboflavin, succinic acid, and/or fumaric acid, coenzyme QlO.
2. Food composition or dietary supplementation according to claim 1, wherein a dose of same has a weight of about 13.8g, said dose being configured in a manner which allows same to be consumed within a restaurant or a bar prior to the consumption of alcohol.
3. Food composition or dietary supplementation according to claim 1 or 2, wherein a dose of same includes a dextrose fraction of about 75.2 mass%.
4. Food composition or dietary supplementation according to at least one of claims 1 to 3, wherein a dose of same includes a Vitamin C fraction of about 7.5 mass%.
5. Food composition or dietary supplementation according to at least one of claims 1 to 4, wherein a dose of same includes a L-glutamine fraction of about 11.28 mass%.
6. Food composition or dietary supplementation according to at least one of claims 1 to 5, wherein a dose of same includes a cysteine fraction of about 3.76 mass%.
7. Food composition or dietary supplementation according to at least one of claims 1 to 6, wherein a dose of same includes a riboflavin fraction of about 0.3 mass%.
8. Food composition or dietary supplementation according to at least one of claims 1 to 7, wherein a dose of same includes a succinic acid fraction of about 0.752 mass%.
9. Food composition or dietary supplementation according to at least one of claims 1 to 8, wherein a dose of same includes a fumaric acid fraction of about 0.752 mass%.
10. Food composition or dietary supplementation according to at least one of claims 1 to 9, wherein a dose of same includes a coenzyme fraction of about 0.451 mass%.
11. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein same is in the form of tablets.
12. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein a dose of same includes a plurality of small tablets or capsules.
13. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein said tablets or capsules are contained in a dosage receptacle.
14. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein said composition is of a sugar-cube type form.
15. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein same is in the form of cryopowder.
16. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein same is in the form of a small drink unit.
17. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein same is in the form of a sirup.
18. Food composition, or dietary supplementation for reducing drug or alcohol induced breast cancer rise including niacin for affecting an alcohol degrading process in particular in respect to ethanol metabolism within the human body, and substances, in particular substances mentioned above, providing the following effects within the human body:
Reducing ethanol metabolism by slowing down the process of ethanol oxidation into acetaldehyde, to prevent accumulation of acetaldehyde in the first place;
- Stimulating the activity of ALDH and avoiding any blockade of its enzymatic activity;
Speeding up the reaction from acetaldehyde to acetic acid and further decomposition in the citrate cycle;
- Improving the levels of those anti-oxidants of the alcohol consumer which specially protect against toxic effects of acetaldehyde.
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA200800602A UA94713C2 (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing risk of alcohol induced diseases |
EA200800427A EA012753B1 (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
CA2611389A CA2611389C (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
EP06762860A EP1909600B1 (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
KR1020077028054A KR101562271B1 (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
AT06762860T ATE554663T1 (en) | 2005-07-29 | 2006-07-27 | COMPOSITION FOR CONTROLLING ALCOHOL METABOLISM AND REDUCING THE RISK OF ALCOHOL-RELATED DISEASES |
KR20137031344A KR101487848B1 (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
SI200631337T SI1909600T1 (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
PL06762860T PL1909600T3 (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
AU2006278823A AU2006278823B2 (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
PT06762860T PT1909600E (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
JP2008523251A JP5371428B2 (en) | 2005-07-29 | 2006-07-27 | Composition for reducing alcohol metabolism and reducing the risk of alcohol-induced diseases |
PCT/EP2006/007466 WO2007017139A1 (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
US11/997,127 US8580750B2 (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
DK06762860.2T DK1909600T3 (en) | 2005-07-29 | 2006-07-27 | Composition for moderation of alcohol metabolism and to reduce the risk of alcohol-caused diseases |
ES06762860T ES2386460T3 (en) | 2005-07-29 | 2006-07-27 | Composition to moderate alcohol metabolism and to reduce the risk of alcohol-induced diseases |
HK08110628.1A HK1117709A1 (en) | 2005-07-29 | 2008-09-24 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
HRP20120489TT HRP20120489T1 (en) | 2005-07-29 | 2012-06-12 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
JP2013091972A JP5785581B2 (en) | 2005-07-29 | 2013-04-25 | Composition for reducing alcohol metabolism and reducing the risk of alcohol-induced diseases |
US14/058,388 US9402849B2 (en) | 2005-07-29 | 2013-10-21 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05016564 | 2005-07-29 | ||
EP05016564.6 | 2005-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007016954A1 true WO2007016954A1 (en) | 2007-02-15 |
Family
ID=36022633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/009152 WO2007016954A1 (en) | 2005-07-29 | 2005-08-24 | Composition for reducing drug or alcohol induced breast cancer risk |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007016954A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012095509A1 (en) * | 2011-01-14 | 2012-07-19 | Tima Foundation | Composition for accelerating alcohol metabolism and for reducing the risk of alcohol induced diseases |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2029220A (en) * | 1978-09-04 | 1980-03-19 | Otsuka Pharma Co Ltd | Amino acid solutions for patients with cancers |
EP0652012A1 (en) * | 1989-03-27 | 1995-05-10 | Albert Naito | Combination of sugars with animo acids and other drugs |
FR2748935A1 (en) * | 1996-05-23 | 1997-11-28 | Clergeaud Jean | Composition to lessen alcohol passing into the bloodstream |
US20020006910A1 (en) * | 2000-05-18 | 2002-01-17 | Dmitri Miasnikov | Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means |
EP1195159A1 (en) * | 2000-10-09 | 2002-04-10 | Rath, Matthias, Dr. med. | Therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer |
WO2003006073A1 (en) * | 2001-07-10 | 2003-01-23 | Penam Investments Pty Ltd | A composition and uses therefor for combating hangover |
WO2004037018A1 (en) * | 2002-10-23 | 2004-05-06 | Quercegen Holdings Llc | Composition for enhancing physical performance |
RU2240789C1 (en) * | 2003-12-24 | 2004-11-27 | Закрытое акционерное общество "НПО ПЦ БИОФИЗИКА" | Agent eliciting hepatoprotective property, for reducing alcoholic intoxication, prophylaxis and elimination of alcoholic intoxication and alcohol withdrawal syndrome |
DE10326822A1 (en) * | 2003-06-11 | 2005-01-05 | Herzpharma Vita-Check Diagnosegeräte GmbH | Dietary supplement, e.g. for increasing general performance, concentration and endurance, comprises NADH, L-carnitine, coenzyme Q10, L-carnosine, succinic acid, ascorbic acid and bioflavonoids |
WO2005077464A1 (en) * | 2004-02-17 | 2005-08-25 | Matuschka-Greinffenclau Markus | Alcohol metabolism moderating composition |
-
2005
- 2005-08-24 WO PCT/EP2005/009152 patent/WO2007016954A1/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2029220A (en) * | 1978-09-04 | 1980-03-19 | Otsuka Pharma Co Ltd | Amino acid solutions for patients with cancers |
EP0652012A1 (en) * | 1989-03-27 | 1995-05-10 | Albert Naito | Combination of sugars with animo acids and other drugs |
FR2748935A1 (en) * | 1996-05-23 | 1997-11-28 | Clergeaud Jean | Composition to lessen alcohol passing into the bloodstream |
US20020006910A1 (en) * | 2000-05-18 | 2002-01-17 | Dmitri Miasnikov | Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means |
EP1195159A1 (en) * | 2000-10-09 | 2002-04-10 | Rath, Matthias, Dr. med. | Therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer |
WO2003006073A1 (en) * | 2001-07-10 | 2003-01-23 | Penam Investments Pty Ltd | A composition and uses therefor for combating hangover |
WO2004037018A1 (en) * | 2002-10-23 | 2004-05-06 | Quercegen Holdings Llc | Composition for enhancing physical performance |
DE10326822A1 (en) * | 2003-06-11 | 2005-01-05 | Herzpharma Vita-Check Diagnosegeräte GmbH | Dietary supplement, e.g. for increasing general performance, concentration and endurance, comprises NADH, L-carnitine, coenzyme Q10, L-carnosine, succinic acid, ascorbic acid and bioflavonoids |
RU2240789C1 (en) * | 2003-12-24 | 2004-11-27 | Закрытое акционерное общество "НПО ПЦ БИОФИЗИКА" | Agent eliciting hepatoprotective property, for reducing alcoholic intoxication, prophylaxis and elimination of alcoholic intoxication and alcohol withdrawal syndrome |
WO2005077464A1 (en) * | 2004-02-17 | 2005-08-25 | Matuschka-Greinffenclau Markus | Alcohol metabolism moderating composition |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Section Ch Week 200506, Derwent World Patents Index; Class B05, AN 2005-055600, XP002373159 * |
LESPERANCE M L ET AL: "Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study.", BREAST CANCER RESEARCH AND TREATMENT. NOV 2002, vol. 76, no. 2, November 2002 (2002-11-01), pages 137 - 143, XP002373640, ISSN: 0167-6806 * |
ZHANG S ET AL: "Dietary carotenoids and vitamins A, C, and E and risk of breast cancer.", JOURNAL OF THE NATIONAL CANCER INSTITUTE 91 (6) 547-556 1999 DEP. OF NUTR., HARVARD SCH. OF PUBLIC HEALTH, 665 HUNTINGON AVE., BOSTON, MA 02115, USA. E-MAIL SHUMIN.ZHANG(A)CHANNING.HARVARD.EDU, 17 March 1999 (1999-03-17), XP002373639 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012095509A1 (en) * | 2011-01-14 | 2012-07-19 | Tima Foundation | Composition for accelerating alcohol metabolism and for reducing the risk of alcohol induced diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1720610B1 (en) | Alcohol metabolism moderating composition | |
US9402849B2 (en) | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases | |
JP2007522254A6 (en) | Alcohol metabolism regulating composition | |
WO2007016953A1 (en) | Composition for reducing alcohol induced liver cancer risk | |
DasGupta | Alcohol and its biomarkers: clinical aspects and laboratory determination | |
WO2007016949A1 (en) | Composition for reducing the risc of alcohol induced neuropathy | |
WO2007016950A1 (en) | Composition for reducing the risk of alcohol induced neurodegenerative disease | |
WO2007016954A1 (en) | Composition for reducing drug or alcohol induced breast cancer risk | |
WO2012095509A1 (en) | Composition for accelerating alcohol metabolism and for reducing the risk of alcohol induced diseases | |
WO2007016952A1 (en) | Composition for reducing the risk of alcohol induced esophagenal and oropharyngolaryngeal cancer | |
WO2007016951A1 (en) | Composition for reducing the risc of alcohol induced pancreatic cancer | |
Jain | ALCOHOL CONSUMPTION, DEPENDENCE, MEDIATED DISORDERS AND CHALLENGES | |
EP3357541A1 (en) | Methylsulfonylmethane composition for reducing blood alcohol content | |
Nolan | An analysis of the effects of various compounds on alcohol and high-fat-diet-induced steatosis in rats and mice | |
KR20030037885A (en) | Composition for elimination of hangover containing naringin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05774902 Country of ref document: EP Kind code of ref document: A1 |